Evidence map›Paper›PMID 41044015›Full record

ReviewSeminars in fetal & neonatal medicine2025

Advancements and potential in the prevention of congenital CMV infection.

Yarlini Vipulanandan, Suresh Boppana, Karen B Fowler, David W Kimberlin

Abstract readReview
In one paragraph

Review in Seminars in fetal & neonatal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yarlini VipulanandanDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Suresh BoppanaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States.
Karen B FowlerDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States.
David W KimberlinDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, United States. Electronic address: dkimberlin@uabmc.edu.

Funding

Valacyclovir Phase I TrialU54AI150225 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MUGAVERO, MICHAEL J · 2019 to 2024
$7.6M
NIAID NIH HHS U54 AI150225
6 · The paper itself

Abstract

Congenital cytomegalovirus (CMV) infection is a large contributor to neurodevelopmental delay and non-genetic sensorineural hearing loss, which can often be delayed in onset. While a majority of CMV infections are asymptomatic in healthy children and adults, periconceptual and early in utero infection can cause clinically significant and potentially long-term sequelae. The complex relationship between congenital CMV infection and maternal immunity provides a challenging backdrop for CMV prevention. Increased awareness of the significance of congenital CMV is reflected in the proliferation of prevention strategies over the past 30 years, including education initiatives, behavioral modifications, and maternal antiviral prophylaxis. This review explores different levels of congenital CMV prevention and highlights a variety of prevention strategies, including the potential for development of effective vaccines for CMV.

Indexed as

Cytomegalovirus InfectionsInfectious Disease Transmission, VerticalPregnancy Complications, InfectiousAntiviral AgentsCytomegalovirusFemaleHumansInfant, NewbornPregnancyAntiviral Agents

Identifiers

PMID41044015
PMCPMC12614814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.